content top

Anecortave Acetate Clinical Update

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: An update of the baseline characteristics of the Anecortave Acetate Risk Reduction Study (AART, C-02-60) evaluating the efficacy and safety of posterior juxtascleral administrations (PJD) of anecortave acetate versus sham in patients at risk for developing sightthreatening choroidal neovascularization (CNV), and of the combination study with an anti-VEGF antiangiogenic agent (Bridge...

Read More

Use of Double Reciprocal Analysis to Compare Pharmacological Treatments for Subfoveal Exudative AMD

Lucian V. Del Priore, MD, PhD (New York, NY), Ankoor R. Shah, BS (New York, NY) PURPOSE: Multiple pharmacological treatments (photodynamic therapy [PDT], Macugen, Lucentis, and Anecortave Acetate [AA]) exist for exudative AMD; typically these treatments are compared to controls in clinical trials but not to one another. We have shown the rate of visual loss in untreated eyes is linear on a double reciprocal Lineweaver-Burke (LB) plot with...

Read More

Anecortave Acetate Depot Suspension for Treatment of Exudative Age-Related Macular Degeneration (AMD)

http://www.evrs.eu/medias/2005/congress/Anecortave-Acetate-depot-suspension-for-treatment-of-exudative-age-related-macular-degeneration (AMD).swf Marc De Smet, MD, PhD – Department of Ophthalmology, University of Amsterdam and the Anecortave Acetate Clinical Study Purpose: To report data from Phase II/III studies evaluating Anecortave Acetate for depot suspension for treatment of exudative AMD. Studies include 1) 24 month study of...

Read More
content top